BMO reiterated its Outperform rating on Silver Standard Resources SSRI. At the same time, the rating agency left its price target on the company's stock unchanged at $40. On Wednesday, SSRI added 1.99% to its value to end the day at $26.17. Its shares lost 0.65% of its value in today's pre-market trading to stand around $25.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
